Novartis to launch phase III trial with Genmab drug this summer
Swiss drug giant Novartis will initiate phase III studies with Genmab-developed ofatumumab as a multiple sclerosis treatment in the second half of 2016. Development is put on hold in all other autoimmune indications.
BY LOUISE WENDT JENSEN
Genmab’s Big Pharma partner Novartis is now ready to advance development of the biotech’s humane antibody ofatumumab as a multiple sclerosis treatment in the last six months of the year, Genmab says in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
